-transparent.png){kind=logo}
Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin. 2006
Weerawat Manosuthi, and
Somnuek Sungkanuparph, and
Ammarin Thakkinstian, and
Sasivimol Rattanasiri, and
Achara Chaovavanich, and
Wisit Prasithsirikul, and
Sirirat Likanonsakul, and
Kiat Ruxrungtham
Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, 11000, Thailand. idweerawat@yahoo.com
Seventy human immunodeficiency virus (HIV)-infected patients receiving rifampicin and 70 HIV-infected patients not receiving rifampicin were enrolled to receive 400 mg of nevirapine-based highly active antiretroviral therapy per day. Mean plasma nevirapine levels at 8 and 12 weeks were lower in patients receiving rifampicin (P=.048). However, virological and immunological outcomes at 24 weeks were not different between the 2 groups (P>.05).
Related Publications
Weerawat Manosuthi, and
Somnuek Sungkanuparph, and
Ammarin Thakkinstian, and
Sasivimol Rattanasiri, and
Achara Chaovavanich, and
Wisit Prasithsirikul, and
Sirirat Likanonsakul, and
Kiat Ruxrungtham
November 2011,
AIDS research and therapy,
Weerawat Manosuthi, and
Somnuek Sungkanuparph, and
Ammarin Thakkinstian, and
Sasivimol Rattanasiri, and
Achara Chaovavanich, and
Wisit Prasithsirikul, and
Sirirat Likanonsakul, and
Kiat Ruxrungtham
January 2002,
Journal of acquired immune deficiency syndromes (1999),
Weerawat Manosuthi, and
Somnuek Sungkanuparph, and
Ammarin Thakkinstian, and
Sasivimol Rattanasiri, and
Achara Chaovavanich, and
Wisit Prasithsirikul, and
Sirirat Likanonsakul, and
Kiat Ruxrungtham
February 2017,
Acta clinica Belgica,
Weerawat Manosuthi, and
Somnuek Sungkanuparph, and
Ammarin Thakkinstian, and
Sasivimol Rattanasiri, and
Achara Chaovavanich, and
Wisit Prasithsirikul, and
Sirirat Likanonsakul, and
Kiat Ruxrungtham
January 2005,
Antiviral therapy,
Weerawat Manosuthi, and
Somnuek Sungkanuparph, and
Ammarin Thakkinstian, and
Sasivimol Rattanasiri, and
Achara Chaovavanich, and
Wisit Prasithsirikul, and
Sirirat Likanonsakul, and
Kiat Ruxrungtham
November 2002,
Journal of acquired immune deficiency syndromes (1999),
Weerawat Manosuthi, and
Somnuek Sungkanuparph, and
Ammarin Thakkinstian, and
Sasivimol Rattanasiri, and
Achara Chaovavanich, and
Wisit Prasithsirikul, and
Sirirat Likanonsakul, and
Kiat Ruxrungtham
December 2004,
The Annals of pharmacotherapy,
Weerawat Manosuthi, and
Somnuek Sungkanuparph, and
Ammarin Thakkinstian, and
Sasivimol Rattanasiri, and
Achara Chaovavanich, and
Wisit Prasithsirikul, and
Sirirat Likanonsakul, and
Kiat Ruxrungtham
October 2002,
International journal of STD & AIDS,
Weerawat Manosuthi, and
Somnuek Sungkanuparph, and
Ammarin Thakkinstian, and
Sasivimol Rattanasiri, and
Achara Chaovavanich, and
Wisit Prasithsirikul, and
Sirirat Likanonsakul, and
Kiat Ruxrungtham
August 1999,
American journal of ophthalmology,
Weerawat Manosuthi, and
Somnuek Sungkanuparph, and
Ammarin Thakkinstian, and
Sasivimol Rattanasiri, and
Achara Chaovavanich, and
Wisit Prasithsirikul, and
Sirirat Likanonsakul, and
Kiat Ruxrungtham
January 2003,
AIDS (London, England),
Weerawat Manosuthi, and
Somnuek Sungkanuparph, and
Ammarin Thakkinstian, and
Sasivimol Rattanasiri, and
Achara Chaovavanich, and
Wisit Prasithsirikul, and
Sirirat Likanonsakul, and
Kiat Ruxrungtham
July 2001,
AIDS (London, England),
